[{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Insys Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2016","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insys Therapeutics \/ Insys Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Insys Therapeutics \/ Insys Therapeutics"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Insys Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2016","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insys Therapeutics \/ Insys Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Insys Therapeutics \/ Insys Therapeutics"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"IL13 Pseudomonas Exotoxin","moa":"IL-13R?2","graph1":"Oncology","graph2":"Phase I","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Insys Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Insys Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2017","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Insys Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Insys Therapeutics \/ Insys Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Insys Therapeutics \/ Insys Therapeutics"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Insys Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Insys Therapeutics \/ Insys Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Insys Therapeutics \/ Insys Therapeutics"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2016","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Undisclosed","graph2":"Phase I","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Undisclosed","graph2":"Phase I","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Insys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Insys Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Insys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Insys Therapeutics \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Insys Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
